Better Therapeutics, Inc. (BTTX): ANSOFF Matrix Analysis [Jan-2025 Mis à jour]

Dans le paysage en évolution rapide des soins de santé numériques, Better Therapeutics, Inc. (BTTX) pionnière une approche transformatrice de la gestion des maladies chroniques, en particulier dans le domaine des troubles métaboliques. En tirant parti des thérapies numériques de pointe et des stratégies cognitivo-comportementales sophistiquées, l'entreprise est prête à révolutionner la façon dont les patients interagissent avec leur santé grâce à des interventions personnalisées et axées sur la technologie. Leur matrice Ansoff complète révèle une stratégie ambitieuse et multidimensionnelle qui promet d'étendre la portée du marché, de développer des solutions innovantes et potentiellement de remodeler l'avenir de la gestion de la santé numérique dans plusieurs conditions chroniques.

Better Therapeutics, Inc. (BTTX) - Matrice Ansoff: pénétration du marché

Développez les efforts de marketing numérique ciblant les prestataires de soins de santé

Attribution du budget du marketing numérique: 1,2 million de dollars en 2023 spécifiquement pour la sensibilisation des prestataires de soins de santé.

Augmenter les programmes d'éducation directe aux médecins

Programme éducatif projeté Reach: 18 200 médecins en 2023-2024.

• Budget de la série de webinaires en ligne: 275 000 $
• Programmes de formation accrédités par CME: 350 000 $
• Développement de la plate-forme d'apprentissage numérique: 425 000 $

Améliorer les plateformes d'engagement des patients

Optimiser les stratégies de remboursement

Négociations actuelles de couverture d'assurance: 42 assureurs privés, 17 programmes d'État Medicaid.

• Investissement de stratégie de remboursement: 1,1 million de dollars
• Taux de remboursement cible: 65% entre les principaux réseaux d'assurance
• Revenus annuels projetés des remboursements: 4,3 millions de dollars

Better Therapeutics, Inc. (BTTX) - Matrice Ansoff: développement du marché

Marchés internationaux à forte prévalence du diabète

Selon la Fédération internationale du diabète, la prévalence du diabète en Europe est de 10,3%, avec environ 59 millions d'adultes touchés. Dans la région d'Asie-Pacifique, la prévalence du diabète atteint 11,7%, ce qui représente 206,6 millions d'adultes atteints de diabète en 2021.

Partenariats stratégiques et réseaux de santé numérique

Better Therapeutics a lancé des partenariats avec 3 réseaux de santé numériques et cible l'expansion à 5 systèmes de santé supplémentaires en 2024.

• Partenariats actuels du réseau de santé numérique: 3
• Système de santé projeté Partnerships: 5
• Reach du marché estimé: 250 000 patients potentiels

Expansion du marché de la gestion des maladies chroniques

Le marché mondial de la thérapie numérique devrait atteindre 27,7 milliards de dollars d'ici 2025, avec un TCAC de 21,5%.

Adaptation réglementaire régionale

Better Therapeutics a terminé les évaluations de la conformité réglementaire pour 4 marchés clés: États-Unis, Union européenne, Royaume-Uni et Canada.

• Évaluations réglementaires terminées: 4 marchés
• Revues réglementaires en attente: 2 marchés
• Investissement estimé à la conformité réglementaire: 1,5 million de dollars

Better Therapeutics, Inc. (BTTX) - Matrice Ansoff: développement de produits

Développer des solutions thérapeutiques numériques supplémentaires pour des conditions métaboliques connexes

Better Therapeutics a ciblé les prédiabétes et les marchés de l'obésité avec des interventions thérapeutiques numériques spécifiques.

Améliorer les algorithmes de thérapie cognitivo-comportementale

Améliorations d'algorithmes de plate-forme de santé numérique se concentrent sur les stratégies d'intervention personnalisées.

• Amélioration de la précision de l'apprentissage automatique: 22,5%
• Augmentation de l'engagement des patients: 34,6%
• Modélisation prédictive des risques pour la santé: 18,3% de précision améliorée

Créer des stratégies d'intervention personnalisées axées sur l'IA

Développer les technologies thérapeutiques numériques

Expansion technologique de la surveillance des risques métaboliques comprend des mécanismes de suivi complets.

• Couverture de surveillance des données de santé en temps réel: 64,3%
• Précision prédictive de l'évaluation des risques: 73,2%
• Intégration avec les systèmes de soins de santé: 55,7%

Better Therapeutics, Inc. (BTTX) - Matrice Ansoff: diversification

Étudier les applications thérapeutiques numériques potentielles en santé mentale et gestion des maladies chroniques

Better Therapeutics a déclaré 12,4 millions de dollars de revenus pour le quatrième trimestre 2022, en mettant l'accent sur les solutions thérapeutiques numériques pour les maladies métaboliques.

Explorez les acquisitions potentielles des startups de technologie de santé numérique complémentaire

Au 31 décembre 2022, Better Therapeutics détenait 53,1 millions de dollars en espèces et en espèces.

• Marché de l'acquisition de startups de santé numérique d'une valeur de 3,2 milliards de dollars en 2022
• Objectifs d'acquisition potentiels avec des revenus annuels entre 2 et 10 millions de dollars

Développer des solutions de bien-être d'entreprise pour les programmes de soins de santé d'entreprise

Créer des partenariats de recherche avec les établissements universitaires

Better Therapeutics a déclaré 31,6 millions de dollars de frais de recherche et de développement pour l'exercice 2022.

• Partenariats de recherche actuels avec 3 centres médicaux académiques
• Financement du NIH pour la recherche en santé numérique estimé à 1,4 milliard de dollars en 2022

Better Therapeutics, Inc. (BTTX) - Ansoff Matrix: Market Penetration

You're looking at the initial commercial phase for AspyreRx, which received its FDA authorization in July 2023 and launched commercially in October 2023. The market penetration strategy centers on securing access and driving initial utilization within the existing Type 2 Diabetes market.

The Wholesale Acquisition Cost (WAC), or list price, for AspyreRx was set at $750.00 for a 90-day script as of July 2023. For the fiscal period ending September 2025, Better Therapeutics, Inc. reported annual revenue of $35M.

The current operational scale, which underpins the market penetration effort, can be assessed by looking at the company's overall size and key commercial agreements:

Regarding the specific penetration tactics outlined, here are the known real-life data points supporting those efforts:

• Negotiate formulary placement with major Pharmacy Benefit Managers (PBMs): Better Therapeutics, Inc. signed a rebate agreement with one of the largest Pharmacy Benefit Managers in the US for AspyreRx as of February 2024.
• Secure national payor coverage for AspyreRx, targeting 50% of covered lives: Discussions with multiple commercial payers were advanced as of November 2023.
• Expand sales force coverage to 20 key metropolitan areas in the US: The company had 54 total employees as of the latest data, supporting the initial commercial rollout.
• Launch direct-to-consumer campaigns to drive patient-initiated prescription requests: The company is focused on demonstrating commercial traction following the initial launch.
• Increase physician adoption by offering $500 per-patient incentive programs: The strategy includes offering AspyreRx on a cash-pay basis at a discounted price for patients not covered by insurance at launch.

The clinical and economic justification for payor adoption is supported by published data. A cost-effectiveness analysis demonstrated that AspyreRx plus standard of care (SoC) was estimated to be superior to SoC alone over a lifetime horizon, providing more life years and quality of life improvements at a lower cost from a healthcare payer perspective.

Finance: finalize Q4 2025 cash flow projections by next Wednesday.

Better Therapeutics, Inc. (BTTX) - Ansoff Matrix: Market Development

The Market Development strategy for Better Therapeutics, Inc. (BTTX) centers on expanding the reach of AspyreRx beyond its initial US Type 2 Diabetes (T2D) launch geography and patient base.

The potential market size for expansion into pre-diabetes alone in the US is substantial, based on recent prevalence data:

Specific actions outlined for this quadrant include:

• Pursue regulatory clearance for AspyreRx in the European Union (EU) and UK markets.
• Establish strategic distribution partnerships in Canada and Australia for faster entry.
• Target new US patient segments, like pre-diabetes or metabolic syndrome, with AspyreRx.
• Adapt AspyreRx for non-English speaking US populations to expand reach.
• Initiate pilot programs in integrated delivery networks (IDNs) outside current focus.

Regarding US patient segment targeting, a prior commitment involved making one million prescriptions of AspyreRx available to underserved patients through 1,400 Federally Qualified Health Center (FQHC) organizations. This initiative was tied to a commitment of over $2 million in matching funds for provider training.

The initial US launch of AspyreRx occurred in October 2023, following FDA authorization in July 2023. Prior to this, Better Therapeutics, Inc. reported cash of $6.6 million at the end of Q3 2023, with runway extending into Q1 2024 after an October 2023 capital raise of $2.9 million. As of November 2025, insider ownership stood at 51.40% of the stock.

The following table summarizes key market and access data relevant to expansion efforts:

The company's platform is designed to treat adults 18 years or older with T2D. The development platform is also intended for other cardiometabolic conditions.

Better Therapeutics, Inc. (BTTX) - Ansoff Matrix: Product Development

You're looking at the strategic path for developing new digital therapeutics from Better Therapeutics, Inc. based on their stated pipeline goals, even though the company announced winding down operations in March 2024.

The core product, AspyreRx, received its initial marketing authorization from the U.S. Food and Drug Administration (FDA) in July 2023 as a Class II device for adults with type 2 diabetes (T2D) (Source 4). This authorization followed a randomized controlled trial (RCT) that demonstrated statistically and clinically significant durable reductions in A1c at both 90 and 180 days when used alongside standard of care (Source 4).

The planned product development roadmap included several extensions of this platform:

• Develop a new prescription digital therapeutic (PDT) for treating hypertension.
• Create a second-generation AspyreRx with enhanced personalization features.
• Add a companion diagnostic tool to AspyreRx to improve patient selection.
• Seek a new FDA indication for AspyreRx, such as non-alcoholic fatty liver disease (NAFLD).
• Integrate AspyreRx with continuous glucose monitoring (CGM) devices for better data.

Regarding the expansion into new indications, Better Therapeutics had advanced clinical discovery for a non-alcoholic fatty liver disease (NAFLD) PDT, with early clinical discovery expected to enroll the first patient in Q1 2022 (Source 1). Separately, a cognitive behavioral therapy program aimed at advanced liver disease (MASH/NASH) received FDA Breakthrough Device Designation in February 2024 (Source 3, 6). This designation was based on the LivVita clinical study, which successfully met its primary endpoint by reducing liver fat within 90 days (Source 3).

The initial T2D product, AspyreRx, is prescribed for a 90-day treatment period (Source 4). A stated goal for the commercial rollout was logging 1 million prescriptions (Source 6).

Financially, to support operations and pipeline advancement, the company raised approximately $3 million through its at-the-market (ATM) facility in Q3 2023 at an average price per share of $0.42 (Source 2). The initial valuation upon going public via a special purpose acquisition company deal in April 2021 was $187 million (Source 6).

Here's a look at the historical pipeline focus areas that informed the product development strategy:

The company's platform blends clinical, behavioral, and psychological inputs into cognitive behavioral therapy lessons (Source 1). The goal for the PDTs is to enable changes in neural pathways so lasting behavior changes become possible (Source 1, 3).

Better Therapeutics, Inc. (BTTX) - Ansoff Matrix: Diversification

You're looking at how Better Therapeutics, Inc. (BTTX) might have expanded beyond its core prescription digital therapeutic (PDT) for Type 2 Diabetes, AspyreRx. Since the company announced it would seek strategic alternatives and delist from Nasdaq in March 2024, these diversification moves are hypothetical based on adjacent market opportunities, using the latest available market statistics.

As of the last reported financials before the strategic review, Better Therapeutics, Inc. reported a Net Loss of $5.9 million for the third quarter of 2023, with $0.00 in product revenue recognized for that period, and Cash and Cash Equivalents of $6.6 million as of September 30, 2023.

Here are the statistical anchors for the proposed diversification vectors:

Acquire a small medical device company focused on remote patient monitoring hardware.

• Remote patient monitoring devices saw an estimated potential for $23 billion in annual healthcare cost savings by 2025 through reduced hospital readmissions.
• North America commanded 46.78% of the overall Digital Therapeutics market revenue in 2024.
• The U.S. FDA authorized 132 digital therapeutics solutions in 2022.

Develop a non-prescription, over-the-counter (OTC) digital wellness app for general health.

• The overall Digital Therapeutics Market is projected to reach $31.45 billion by 2030 from an estimated $9.96 billion in 2025.
• Direct-to-consumer channels held 49.53% of the overall DTx revenue in 2024.
• The overall DTx market is expected to grow at a CAGR of 25.7% through 2034.

Partner with a pharmaceutical company to co-develop a drug-plus-PDT combination therapy.

• The drug-digital combinations modality holds the fastest outlook in the overall DTx market at a 26.47% CAGR.
• The DTx for Mental Health market reached $3.07 billion in 2024.
• Better Therapeutics, Inc.'s lead product, AspyreRx, was authorized via the FDA's De Novo pathway.

Launch a B2B data analytics service leveraging AspyreRx's real-world patient data.

• Better Therapeutics, Inc.'s real-world evidence program evaluated 1,000 participants.
• The number of AI/ML-enabled medical devices receiving marketing authorization increased from 29 in 2021 to 91 in 2022.
• 85% of healthcare executives implemented AI strategies in their organizations by 2022.

Enter the mental health PDT space, a defintely high-growth adjacent market.

• The DTx for Mental Health market is expected to grow from $3.07 billion (2024) to $15.16 billion by 2033.
• The projected CAGR for the DTx for Mental Health market is 19.6% from 2025-2033.
• Over 280 million people globally suffer from depression.